GLMP

GLMP is a heavily glycosylated type I lysosomal integral membrane protein that functions as an essential accessory subunit of the major facilitator superfamily transporter MFSD1, together forming a heterodimeric lysosomal dipeptide uniporter that exports cationic, neutral, and anionic dipeptides from the lysosomal lumen (PMID:38839979). GLMP reaches lysosomes via a C-terminal tyrosine-based sorting motif and is required to stabilize MFSD1 at the lysosomal membrane; reciprocal knockout of either gene produces identical phenotypes including splenomegaly, progressive liver fibrosis, lipofuscin accumulation, and metabolic dysregulation characterized by increased hepatic lipogenesis and glycolytic reprogramming (PMID:19489740, PMID:31661432, PMID:24487409, PMID:26047317). GLMP additionally associates with GIMAP5 in a tripartite MFSD1–GLMP–GIMAP5 lysosomal complex that maintains GIMAP5 protein levels and is required for lymphocyte survival and liver homeostasis, as germline loss of any single component causes lymphopenia and hepatic pathology (PMID:38055739). GLMP expression is transcriptionally repressed by BRG1 and post-transcriptionally stabilized by NAT10-mediated ac4C modification of its mRNA (PMID:34158256, PMID:37914704).

1. 2007 Medium

   The first functional study attributed transcription-factor and PPARα co-activator activities to NCU-G1/GLMP, suggesting a dual nuclear/membrane role that framed subsequent investigations into its primary cellular function.

   Evidence EMSA and reporter assays in Drosophila S2 cells

   PMID:18021396

   Open questions at the time

   • No mutagenesis or structural data confirmed direct DNA binding
   • Activity demonstrated only in heterologous insect cells, not validated in mammalian systems
   • Subsequent studies repositioned GLMP as a lysosomal membrane protein rather than a transcription factor
2. 2009 High

   Establishing GLMP as a lysosomal protein resolved the question of its primary subcellular localization and revealed that heavy N-glycosylation and a C-terminal tyrosine-based motif govern its trafficking and apparent molecular mass.

   Evidence Immunofluorescence co-localization with LAMP-1, subcellular fractionation, N-glycosidase F digestion, and Y400A mutagenesis

   PMID:19489740

   Open questions at the time

   • Lysosomal function of GLMP was unknown
   • Whether glycosylation served a protective or functional role was not addressed
3. 2014 High

   Knockout mouse studies demonstrated that GLMP is essential for hepatic homeostasis, as its loss causes spontaneous liver fibrosis, lipofuscin and iron accumulation in Kupffer cells, and oxidative stress — providing the first evidence of organismal consequence.

   Evidence Gene-trap knockout mouse with histological, immunohistochemical, and biochemical liver analysis

   PMID:24487409

   Open questions at the time

   • Molecular mechanism linking GLMP loss to liver fibrosis was unknown
   • Whether GLMP acted alone or as part of a complex was unresolved
4. 2015 High

   Metabolic characterization of GLMP-null hepatocytes revealed that GLMP loss causes increased glucose flux, de novo lipogenesis, and lipid accumulation, establishing GLMP as a regulator of hepatic metabolic partitioning.

   Evidence Metabolic flux assays in primary Glmp-KO hepatocytes, blood biochemistry, gene expression profiling

   PMID:26047317

   Open questions at the time

   • Whether metabolic dysregulation was a direct effect of impaired lysosomal transport or secondary to liver damage was unclear
   • GLMP's molecular partner and transport substrate remained unidentified
5. 2016 Medium

   Extension to skeletal muscle showed that GLMP deficiency shifts myotubes toward glycolytic metabolism with reduced PPAR and lipid oxidation gene expression, demonstrating that GLMP's metabolic role extends beyond the liver.

   Evidence Substrate oxidation and gene expression assays in primary myotubes from Glmp-KO mice

   PMID:26707125

   Open questions at the time

   • Mechanism of PPAR downregulation in GLMP-null muscle was not established
   • Whether this reflects a cell-autonomous lysosomal defect versus systemic metabolic changes was unresolved
6. 2019 High

   Identification of GLMP as the obligate partner of the transporter MFSD1 revealed that the two proteins form a tightly linked lysosomal complex and are mutually required for stability, resolving the question of GLMP's direct molecular function at the lysosomal membrane.

   Evidence Co-immunoprecipitation, lysosome proteomics, and phenotypic identity of reciprocal Mfsd1 and Glmp knockout mice

   PMID:31661432

   Open questions at the time

   • The transport substrate of the MFSD1–GLMP complex was unknown
   • Structural basis of the heterodimer was unresolved
7. 2021 Medium

   ChIP and knockdown studies showed that BRG1 directly binds the GLMP promoter and represses its transcription, connecting chromatin remodeling to GLMP-dependent lipid metabolism in hepatocellular carcinoma cells.

   Evidence ChIP, siRNA knockdown, lipid staining, and epistasis experiments in HCC cell lines

   PMID:34158256

   Open questions at the time

   • Whether BRG1-mediated GLMP repression operates in normal hepatocytes or is cancer-specific was not tested
   • Downstream pathway activation (PIK3AP1/PI3K/AKT) was not validated with genetic rescue
8. 2023 High

   Two studies expanded GLMP's interactome and regulatory network: proteomics identified a tripartite MFSD1–GLMP–GIMAP5 complex required for lymphocyte survival and liver homeostasis, while ac4C-RIP showed that NAT10-mediated mRNA acetylation stabilizes GLMP transcripts to activate MAPK/ERK signaling in head and neck cancer.

   Evidence Proteomic complex identification with matching triple-KO phenotypes (PNAS); NAT10 gain/loss-of-function, ac4C-RIP, and in vivo metastasis models (Cell Death & Disease)

   PMID:37914704 PMID:38055739

   Open questions at the time

   • How GIMAP5 stability depends on MFSD1–GLMP at a structural level is unknown
   • Whether GLMP-driven MAPK/ERK activation in cancer reflects its dipeptide transport function or an independent activity is unresolved
   • The stoichiometry and assembly pathway of the MFSD1–GLMP–GIMAP5 complex are not defined
9. 2024 High

   Cryo-EM structure determination and reconstitution in proteoliposomes definitively established MFSD1–GLMP as a lysosomal dipeptide uniporter, resolving the substrate identity and transport mechanism that had been sought since the complex was identified.

   Evidence Cryo-EM of outward-open dipeptide-bound MFSD1–GLMP heterodimer, untargeted lysosome metabolomics, electrophysiology in Xenopus oocytes, isotope tracer and fluorescence transport assays in proteoliposomes

   PMID:38839979

   Open questions at the time

   • Structural basis for GLMP's role in stabilizing MFSD1 versus direct involvement in substrate selectivity requires further mutagenesis
   • Whether dipeptide transport deficiency alone explains all KO phenotypes (fibrosis, lymphopenia) is not established
10. 2025 Medium

    GLMP was shown to promote EGFR-TKI resistance in lung cancer by stabilizing RhoA through regulation of its ubiquitination and by enhancing autophagic flux via lysosomal hyperactivity, expanding GLMP's known roles into drug-resistance mechanisms.

    Evidence Overexpression/knockdown in NSCLC cells and xenograft models, RhoA ubiquitination assays, autophagy flux assays, pharmacological rescue

    PMID:41298761

    Open questions at the time

    • Whether GLMP regulates RhoA ubiquitination directly or indirectly through dipeptide transport is unknown
    • Single-lab finding not yet independently replicated
    • Relevance of this mechanism beyond osimertinib-resistant NSCLC is untested

• Key open questions include whether impaired dipeptide export fully explains the liver fibrosis, lymphopenia, and metabolic phenotypes of GLMP-null animals; how GLMP structurally contributes to MFSD1 folding and stability versus directly participating in transport; and what physiological signals regulate GLMP expression in non-cancerous tissues.
• No disease-rescue experiment has tested whether restoring dipeptide transport alone reverses KO phenotypes
• The structural role of GLMP's glycosylated luminal domain in the heterodimer is not mechanistically defined
• Physiological transcriptional and post-transcriptional regulation of GLMP outside cancer contexts is largely unexplored